Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

Cancer

Volumn 121, Issue 10, 2015, Pages 1654-1661

  Hainsworth, John D ^a   Daugaard, Gedske ^b   Lesimple, Thierry ^c   Hübner, Gerdt ^d   Greco, F Anthony ^a   Stahl, Michael J ^e   Büschenfelde, Christian Meyer Zum ^f   Allouache, Djelila ^g   Penel, Nicolas ^h   Knoblauch, Poul ⁱ   Fizazi, Karim S ^j  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Eugene Marquis Center   (France)

^d Oldenburg in Holstein   (Germany)

^e Hospital Essen Mitte   (Germany)

^f Asklepios Clinic Altona   (Germany)

^g Department of Medical Oncology Francois Baclesse Regional Center for the Fight Against Cancer   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ BioAlliance Pharma   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

belinostat; carboplatin; carcinoma of unknown primary site; paclitaxel

Indexed keywords

BELINOSTAT; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DEHYDRATION; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PACLITAXEL; SULFONAMIDES; TREATMENT FAILURE;

EID: 84929044205     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29229     Document Type: Article

References (44)

1. Massard C, Loriot Y, Fizazi K,. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 2011; 8: 701-710.
2. Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD,. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J. 2001; 7: 203-212.
3. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010; 16: 70-75.
4. Huebner G, Link H, Kohne CH, et al. German CUP Study Group. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009; 100: 44-49.
5. Moller AK, Pedersen KD, Gothelf A, Daugaard G,. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol. 2010; 49: 423-430.
6. Gross-Goupil M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012; 48: 721-727.
7. Pittman KB, Olver IN, Koczwara B, et al. Adelaide Cancer Trials and Education Collaborative (ACTEC). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer. 2006; 95: 1309-1313.
8. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer. 2004; 100: 1257-1261.
9. Palmeri S, Lorusso V, Palmeri L, et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer. 2006; 107: 2898-2905.
10. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; 28: 4485-4491.
11. Kaufman JL, Fabre C, Lonial S, Richardson PG,. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk. 2013; 13: 370-376.
12. Marks PA, Richon VM, Miller T, Kelly WK,. Histone deacetylase inhibitors. Adv Cancer Res. 2004; 91: 137-168.
13. Johnstone RW,. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002; 1: 287-299.
14. Vigushin DM, Coombes RC,. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002; 13: 1-13.
15. Qian X, LaRochelle WJ, Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006; 5: 2086-2095.
16. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M,. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer. 2008; 122: 1400-1410.
17. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008; 14: 804-810.
18. Lassen U, Molife LR, Sorensen M, et al. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer. 2010; 103: 12-17.
19. Foss F, Pohlman B, Jacobsen E, et al. Phase II open-label trial of belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. Ann Oncol. 2008; 19: 154. Abstract 241.
20. Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010; 46: 1573-1579.
21. Barriuso J, Daugaard G, Frentzas S, et al. Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder. Eur J Cancer. 2008; 6 (suppl): 67-68.
22. Eisenhauer E, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
23. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 1748-1756.
24. El-Rayes BF, Shields AF, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol. 2005; 28: 152-156.
25. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000; 18: 3101-3107.
26. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
27. Culine S, Kramar A, Saghatchian M, et al. French Study Group on Carcinomas of Unknown Primary. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002; 20: 4679-4683.
28. Culine S, Lortholary A, Voigt JJ, et al. French Study Group on Carcinomas of Unknown Primary. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003; 21: 3479-3482.
29. Schneider BJ, El-Rayes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer. 2007; 110: 770-775.
30. Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002; 20: 1651-1656.
31. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA. 1998; 95: 3003-3007.
32. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6: 38-51.
33. Marchion D, Munster P,. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007; 7: 583-598.
34. Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA,. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011; 13: 493-503.
35. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol. 2010; 23: 814-823.
36. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD,. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010; 15: 500-506.
37. Ades F, de Azambuja E, Daugaard G, et al. Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). J Chemother. 2013; 25: 239-246.
38. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31: 217-223.
39. Greco FA, Lennington WJ, Spigel DR, Varadhachary GR, Hainsworth JD,. Carcinoma of unknown primary site: outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy [serial online]. J Cancer Ther. 2012; 3: 37-43.
40. Varadhachary GR, Karanth S, Qiao W, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014; 19: 479-484.
41. Gross-Goupil M, Massard C, Lesimple T, et al. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie. 2012; 35: 54-55.
42. Dova L, Pentheroudakis G, Georgiou I, et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007; 24: 79-86.
43. Penley WC, Spigel DR, Greco FA, et al. Confirmation of non-small cell lung cancer (NSCLC) diagnosis using ALK testing and genetic profiling in patients presenting with carcinoma of unknown primary site (CUP) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract e19062.
44. Gatalica Z, Millis S, Bender R, et al. Molecular profiling cancers of unknown primary site (CUP): paradigm shift in management of CUP [abstract]. Eur J Cancer. 2011; 47 (suppl 2). Abstract LBA39.